The genetic deletion of TRF1 impairs tumor initiation and progression in various mouse GBM subtypes by inducing telomere damage and reducing stemness in glioma stem cells, validating TRF1 as a favorable target in glioblastoma treatment [112]. Here, TERF1 is linked to central nervous system cancer.